New studies demonstrate the ability of Foundation Medicine’s portfolio of tests to improve treatment options for patients, and reinforce the company’s role as an essential partner to researchers
April 05, 2022 07:05 AM Eastern Daylight Time
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced that the company and its collaborators will present a total of nine studies, including two clinical science symposia presentations and seven poster discussions, at the 2022 American Association for Cancer Research (AACR) Annual Meeting from April 8-13.
“Data being presented at this year’s AACR meeting emphasize our role as an essential partner for our collaborators who are working to identify patients most likely to benefit from new precision therapies”Tweet this
Highlights of these presentations include:
- Two studies spotlighting the concordance between Foundation Medicine’s tissue and blood-based comprehensive genomic profiling (CGP) tests and their complementary value as tools to provide genomic insights to researchers and clinicians.
- Data on Foundation Medicine’s new algorithm to predict homologous recombination deficiency (HRD) status and identify patients who may be candidates for PARP inhibitors across multiple disease types. Patient identification for PARP inhibitors remains a challenge, but these findings suggest that HRD status, including indel and copy number features, is associated with instability beyond ovarian cancer.
- A new study leveraging existing data to identify 165 ancestry-associated features across multiple common cancer types. These findings help address the lack of knowledge about ancestry-specific alterations in an effort to overcome barriers to implementing precision medicine, including inequities in genetic testing, targeted treatment and clinical trial design for cancer patients from underserved populations.
“Data being presented at this year’s AACR meeting emphasize our role as an essential partner for our collaborators who are working to identify patients most likely to benefit from new precision therapies,” said Priti Hegde, PhD, chief scientific officer at Foundation Medicine. “Our research also highlights how the data derived from our portfolio of tests can shape the future of cancer care and research, including through our novel HRD algorithm.”
The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at AACR, please visit AACR.org.
Follow Foundation Medicine on Twitter and LinkedIn for more updates from #AACR22 and visit us in person at booth #2301.
| Abstract # | Title | Collaborator | Product |
| Clinical Science Symposia | |||
| 2139Monday, April 112:35 PM – 2:50 PM | Evaluation of tissue- and plasma-derived tumor mutational burden and genomic alterations of interest from the CheckMate 848 clinical trial | Bristol Myers Squibb | Clinical trial assay based on FoundationOne® CDx & Foundation Medicine bTMB Clinical Trial Assay |
| CT031Monday, April 113:20 PM – 3:30 PM | TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity | Pfizer | Clinical trial assay based on FoundationOne® CDx |
| Posters | |||
| 57/18Sunday, April 101:30 PM – 5:00 PM | Patients with germline ATM mutations develop clonal hematopoiesis characterized by co-occurrence of multiple somatic ATM alterations | FoundationCore® | |
| 753/9Monday, April 119:00 AM – 12:30 PM | Comprehensive genomic profiling (CGP) reveals site-specific enrichment of immunotherapy biomarkers and targetable alterations in non-small cell lung cancer (NSCLC) metastasis | FoundationCore® | |
| 798/7Monday, April 119:00 AM – 12:30 PM | Comprehensive genomic profiling of tissue and liquid biopsies reveals the landscape of reversion mutations | FoundationCore® | |
| 1166/13Monday, April 119:00 AM – 12:30 PM | Leveraging existing data to identify ancestry-associated features across multiple cancer types | Dana Farber Cancer Institute | FoundationCore® |
| 1243/15Monday, April 119:00 AM – 12:30 PM | Identification of aneuploidy biomarkers associated with response to first-line treatment of metastatic pancreatic cancer | Foundation Medicine and Flatiron Health’s Clinicogenomic Database | |
| 1249/21Monday, April 119:00 AM – 12:30 PM | Development of a pan-cancer algorithm to predict homologous recombination deficiency and sensitivity to PARPi therapy | University of Minnesota | Foundation Medicine and Flatiron Health’s Clinicogenomic Database & FoundationCore® |
| 3413/19Tuesday, April 121:30 PM – 5:00 PM | Clinical utility of circulating tumor DNA sequencing with a large panel: The experience of Gustave Roussy/ National Center for Precision Medicine (PRISM) | Gustave Roussy Cancer Center | FoundationOne® Liquid CDx |
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter and LinkedIn.
Foundation Medicine®, FoundationOne®, and FoundationCore® are registered trademarks of Foundation Medicine, Inc.
Source: Foundation Medicine
Contacts
Abigail Alderman, 781-534-3210
newsroom@foundationmedicine.com